Citadel Advisors’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.9M | Buy |
3,566,504
+3,296,013
| +1,219% | +$13.9M | ﹤0.01% | 2696 |
|
|
2025
Q4 | $744K | Buy |
270,491
+109,830
| +68% | +$313K | ﹤0.01% | 8074 |
|
|
2025
Q3 | $551K | Buy |
160,661
+116,201
| +261% | +$424K | ﹤0.01% | 8894 |
|
|
2025
Q2 | $153K | Sell |
44,460
-463,628
| -91% | -$1.22M | ﹤0.01% | 10938 |
|
|
2025
Q1 | $1.08M | Buy |
508,088
+293,310
| +137% | +$880K | ﹤0.01% | 6785 |
|
|
2024
Q4 | $685K | Buy |
214,778
+202,754
| +1,686% | +$1.66M | ﹤0.01% | 7874 |
|
|
2024
Q3 | $161K | Sell |
12,024
-563,525
| -98% | -$7.49M | ﹤0.01% | 10472 |
|
|
2024
Q2 | $5.74M | Sell |
575,549
-651,194
| -53% | -$9.41M | ﹤0.01% | 3536 |
|
|
2024
Q1 | $14.6M | Buy |
+1,226,743
| New | +$10.5M | ﹤0.01% | 2433 |
|
|
2023
Q3 | – | Sell |
-16,678
| Closed | -$111K | – | 14336 |
|
|
2023
Q2 | $111K | Buy |
+16,678
| New | +$101K | ﹤0.01% | 10765 |
|
|
2023
Q1 | – | Sell |
-30,564
| Closed | -$75.5K | – | 14765 |
|
|
2022
Q4 | $75.5K | Buy |
30,564
+27,973
| +1,080% | +$92.2K | ﹤0.01% | 11597 |
|
|
2022
Q3 | $6K | Sell |
2,591
-1,511
| -37% | -$5.17K | ﹤0.01% | 12344 |
|
|
2022
Q2 | $13K | Sell |
4,102
-8,592
| -68% | -$26.2K | ﹤0.01% | 12522 |
|
|
2022
Q1 | $46K | Buy |
+12,694
| New | +$46.3K | ﹤0.01% | 12842 |
|
|
2021
Q4 | – | Sell |
-1,080
| Closed | -$7K | – | 13844 |
|
|
2021
Q3 | $7K | Sell |
1,080
-4,055
| -79% | -$27.6K | ﹤0.01% | 13695 |
|
|
2021
Q2 | $41K | Sell |
5,135
-7,098
| -58% | -$62.2K | ﹤0.01% | 13405 |
|
|
2021
Q1 | $134K | Buy |
12,233
+2,742
| +29% | +$41.4K | ﹤0.01% | 12174 |
|
|
2020
Q4 | $43K | Buy |
9,491
+3,554
| +60% | +$15.7K | ﹤0.01% | 10616 |
|
|
2020
Q3 | $35K | Sell |
5,937
-1,607
| -21% | -$10.5K | ﹤0.01% | 9719 |
|
|
2020
Q2 | $42K | Buy |
7,544
+5,224
| +225% | +$33.6K | ﹤0.01% | 9375 |
|
|
2020
Q1 | $12K | Sell |
2,320
-1,351
| -37% | -$10.2K | ﹤0.01% | 9396 |
|
|
2019
Q4 | $23K | Sell |
3,671
-2,704
| -42% | -$11.9K | ﹤0.01% | 8916 |
|
|
2019
Q3 | $20K | Buy |
6,375
+2,474
| +63% | +$8.96K | ﹤0.01% | 8937 |
|
|
2019
Q2 | $16K | Sell |
3,901
-657
| -14% | -$2.75K | ﹤0.01% | 8973 |
|
|
2019
Q1 | $17K | Buy |
4,558
+2,246
| +97% | +$8.76K | ﹤0.01% | 9088 |
|
|
2018
Q4 | $7K | Buy |
+2,312
| New | +$9.9K | ﹤0.01% | 8964 |
|
|
2018
Q2 | – | Sell |
-13,623
| Closed | -$57K | – | 8836 |
|
|
2018
Q1 | $57K | Buy |
13,623
+4,196
| +45% | +$18.5K | ﹤0.01% | 7892 |
|
|
2017
Q4 | $38K | Buy |
9,427
+6,437
| +215% | +$30K | ﹤0.01% | 7702 |
|
|
2017
Q3 | $15K | Buy |
+2,990
| New | +$16.8K | ﹤0.01% | 7406 |
|
|
2017
Q2 | – | Sell |
-1,451
| Closed | -$9K | – | 7514 |
|
|
2017
Q1 | $9K | Sell |
1,451
-4,552
| -76% | -$26.6K | ﹤0.01% | 7341 |
|
|
2016
Q4 | $35K | Buy |
6,003
+2,709
| +82% | +$16.6K | ﹤0.01% | 6947 |
|
|
2016
Q3 | $24K | Sell |
3,294
-100
| -3% | -$762 | ﹤0.01% | 7003 |
|
|
2016
Q2 | $30K | Sell |
3,394
-7,024
| -67% | -$67.2K | ﹤0.01% | 6520 |
|
|
2016
Q1 | $94K | Buy |
+10,418
| New | +$82K | ﹤0.01% | 6052 |
|
|
2015
Q3 | – | Sell |
-1,486
| Closed | -$22K | – | 8886 |
|
|
2015
Q2 | $22K | Buy |
+1,486
| New | +$24.1K | ﹤0.01% | 8101 |
|
|
2015
Q1 | – | Sell |
-3,103
| Closed | -$45K | – | 8536 |
|
|
2014
Q4 | $45K | Buy |
+3,103
| New | +$49.1K | ﹤0.01% | 7265 |
|
|
2014
Q3 | – | Sell |
-6,309
| Closed | -$197K | – | 8123 |
|
|
2014
Q2 | $197K | Buy |
+6,309
| New | +$158K | ﹤0.01% | 5581 |
|
|
2014
Q1 | – | Sell |
-3,506
| Closed | -$18K | – | 7854 |
|
|
2013
Q4 | $18K | Buy |
+3,506
| New | +$18.5K | ﹤0.01% | 6517 |
|
Other funds holding CATX
APM
TCM
CC
OM
VCM
AAA
Citadel Advisors's CATX Position: Q1 2026 in Review
Citadel Advisors increased its Perspective Therapeutics (CATX) stake by 1,219% in Q1 2026, buying an estimated $13.9M and bringing the position to 3,566,504 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2696.
Citadel Advisors first reported a position in CATX in Q4 2013 and has held it in 38 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.
- Citadel Advisors held 3,566,504 shares of Perspective Therapeutics worth $14.9M as of Q1 2026.
- Citadel Advisors bought 3,296,013 Perspective Therapeutics shares in Q1 2026, an estimated $13.9M.
- Perspective Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2696 holding.
- Citadel Advisors first reported a position in Perspective Therapeutics in Q4 2013 and has held it in 38 quarters since.
- 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.